Co-treatment with BAZ1A Inhibitor, Cpd-2, Sensitizes ER Positive Breast Cancer Cells to Tamoxifen
Conference Year
January 2023
Abstract
Breast cancers expressing the Estrogen Receptor (ER-a) can be effectively treated using SERMs (selective estrogen receptor modulators), such as 4-hydroxy-tamoxifen (4-OH-T). Unfortunately, ~30% of patients who receive these treatments will develop endocrine therapy resistance (ETR). We have identified the chromatin remodeling factor BAZ1A as a therapeutic target in ETR breast cancer. Here, we exploit the bromodomain of BAZ1A, and ask if treatment with the Cpd-2 inhibitor can sensitize ER+ breast cancer cells to 4-OH-T. Our results indicate Cpd-2 treatment sensitizes breast cancer cells to 4-OH-T treatment, and support further investigation of BAZ1A as a modulator of ER sensitivity and activity.
Primary Faculty Mentor Name
Seth Frietze
Status
Graduate
Student College
Graduate College
Program/Major
Cellular, Molecular and Biomedical Sciences
Primary Research Category
Life Sciences
Co-treatment with BAZ1A Inhibitor, Cpd-2, Sensitizes ER Positive Breast Cancer Cells to Tamoxifen
Breast cancers expressing the Estrogen Receptor (ER-a) can be effectively treated using SERMs (selective estrogen receptor modulators), such as 4-hydroxy-tamoxifen (4-OH-T). Unfortunately, ~30% of patients who receive these treatments will develop endocrine therapy resistance (ETR). We have identified the chromatin remodeling factor BAZ1A as a therapeutic target in ETR breast cancer. Here, we exploit the bromodomain of BAZ1A, and ask if treatment with the Cpd-2 inhibitor can sensitize ER+ breast cancer cells to 4-OH-T. Our results indicate Cpd-2 treatment sensitizes breast cancer cells to 4-OH-T treatment, and support further investigation of BAZ1A as a modulator of ER sensitivity and activity.